may 1st dndn decision, page-10

Boiler posted some interesting links to finance.yahoo charts for other immunotherapy companies,

Refer to http://hotcopper.com.au/post_threadview.asp?fid=1&tid=1142194&msgno=5227968#5227968

All companies had mcaps between $45M and $160M USD.

If DNDN is approved, and we have a reasonable trial result, we could have a nice re-rating. If VHL gets even into the bottom part of that range it's a 3 bagger from today (approx). If the entire sector, globally, gets rerated... wow. Will be interesting.